EUVIMEDEUVIMED entdecken
Open Access

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases

Killian Donovan, William G Herrington, Guillaume Paré, Marie Pigeyre, Richard Haynes, Rebecca Sardell, Adam S Butterworth, Lasse Folkersen, Stefan Gustafsson, Qin Wang, Colin Baigent, Anders Mälarstig und 3 weitere

Clinical Journal of the American Society of Nephrology · 2023-01 · 18 (1) · 17-27

DOI: 10.2215/cjn.05080422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2023-01. Verfasst von Killian Donovan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United K…. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease, Heart Failure. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation, Department of Health, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fibroblast growth factor-23 (FGF-23) is associated with a range of cardiovascular and noncardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding.

Methods

SCALLOP Consortium data of 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease ( n =26,266 events), nonatherosclerotic cardiovascular disease ( n =12,652), and noncardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n =181,249 cases), MEGASTROKE (stroke, n =34,217), and HERMES (heart failure, n =47,309).

Results

We identified 34 independent variants for circulating FGF-23, which formed a validated genetic score. There were no associations between genetically predicted FGF-23 and any of the cardiovascular or noncardiovascular outcomes. In UK Biobank, the odds ratio (OR) for any atherosclerotic cardiovascular disease per 1-SD higher genetically predicted logFGF-23 was 1.03 (95% confidence interval [95% CI], 0.98 to 1.08), and for any nonatherosclerotic cardiovascular disease, it was 1.01 (95% CI, 0.94 to 1.09). The ORs in the case-control consortia were 1.00 (95% CI, 0.97 to 1.03) for coronary artery disease, 1.01 (95% CI, 0.95 to 1.07) for stroke, and 1.00 (95% CI, 0.95 to 1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalities.

Conclusions

Genetically predicted FGF-23 levels are not associated with atherosclerotic and nonatherosclerotic cardiovascular diseases, suggesting no important causal link. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_01_10_CJN05080422.mp3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCardiovascular DiseasesCoronary Artery DiseaseHeart FailureStrokeHumansCarotid Intima-Media ThicknessFibroblast Growth Factor-23Mendelian Randomization AnalysisPolymorphism, Single NucleotideRisk Factors

Substanzen

Fibroblast Growth Factor-23FGF23 protein, human

Autor:innen und Institutionen

  • Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom.
  • Medical Research Council Population Health Research Unit at the University of Oxford, NDPH, Oxford, United Kingdom.
  • Oxford Kidney Unit, Churchill Hospital, Oxford, United Kingdom.
  • Population Health Research Institute, McMaster University, Hamilton, Canada.
  • BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Danish National Genome Center, Copenhagen, Denmark.

Förderung

  • British Heart Foundation
  • Department of Health
  • Medical Research Council

Zitieren

APA

Donovan, K., Herrington, W. G., Paré, G., Pigeyre, M., Haynes, R., Sardell, R., Butterworth, A. S., Folkersen, L., Gustafsson, S., Wang, Q., Baigent, C., Mälarstig, A., Holmes, M. V., Staplin, N., & on behalf of the SCALLOP Consortium (2023). Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. Clinical Journal of the American Society of Nephrology, 18(1), 17-27. https://doi.org/10.2215/cjn.05080422

Vancouver

Donovan K, Herrington WG, Paré G, Pigeyre M, Haynes R, Sardell R, et al. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. Clinical Journal of the American Society of Nephrology. 2023;18(1):17-27. doi:10.2215/cjn.05080422

BibTeX
@article{Donovan2023,
  author = {Donovan, Killian and Herrington, William G and Paré, Guillaume and Pigeyre, Marie and Haynes, Richard and Sardell, Rebecca and Butterworth, Adam S and Folkersen, Lasse and Gustafsson, Stefan and Wang, Qin and Baigent, Colin and Mälarstig, Anders and Holmes, Michael V and Staplin, Natalie and on behalf of the SCALLOP Consortium, on behalf of the SCALLOP Consortium},
  title = {Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {17--27},
  doi = {10.2215/cjn.05080422}
}
Kostenlos starten →